Icahn Speculation Around Valeant (VRX) Grows Following Interview
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil rises as Trump repeats Iran attack threat
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Valeant Pharma (VRX) At Lows Into the Close
November 4, 2015 3:43 PM ESTValeant Pharma (NYSE: VRX) is trading near the lows into the close. Shares are down 6% to $92. Today's senate hearing on drug pricing, the 'missing piece' hit piece and reports from Reuters that OptumRx caught on to odd billing at Valeant-linked pharmacy more than a year ago, are all weighting.
... More